148 related articles for article (PubMed ID: 2650711)
1. Plasma angiotensin II and the antihypertensive action of angiotensin-converting enzyme inhibition.
Nussberger J; Waeber B; Brunner HR
Am J Hypertens; 1989 Apr; 2(4):286-93. PubMed ID: 2650711
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of ACE inhibition.
Nussberger J; Waeber B; Brunner HR
Cardiology; 1989; 76 Suppl 2():11-22. PubMed ID: 2670217
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin converting enzyme inhibition: discrepancy between antihypertensive effect and suppression of enzyme activity.
Waeber B; Nussberger J; Juillerat L; Brunner HR
J Cardiovasc Pharmacol; 1989; 14 Suppl 4():S53-9. PubMed ID: 2483430
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin converting enzyme inhibition and renin inhibition.
Nussberger J; Waeber B; Brunner HR
J Hypertens Suppl; 1989 Apr; 7(2):S75-9. PubMed ID: 2666618
[TBL] [Abstract][Full Text] [Related]
5. Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system.
Schalekamp MA; Derkx FH; van den Meiracker AH
J Hypertens Suppl; 1992 Dec; 10(7):S157-64. PubMed ID: 1291650
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system.
Brunner HR; Nussberger J; Waeber B
J Hypertens Suppl; 1993 Apr; 11(3):S53-8. PubMed ID: 8315521
[TBL] [Abstract][Full Text] [Related]
7. Effects of Ramipril on the Aldosterone/Renin Ratio and the Aldosterone/Angiotensin II Ratio in Patients With Primary Aldosteronism.
Guo Z; Poglitsch M; Cowley D; Domenig O; McWhinney BC; Ungerer JPJ; Wolley M; Stowasser M
Hypertension; 2020 Aug; 76(2):488-496. PubMed ID: 32507039
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibition versus blockade of the renin-angiotensin system.
Brunner HR; Waeber B; Nussberger J
Am J Med; 1989 Dec; 87(6B):15S-18S. PubMed ID: 2690609
[TBL] [Abstract][Full Text] [Related]
9. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists.
Campbell DJ
Clin Exp Pharmacol Physiol Suppl; 1996; 3():S125-31. PubMed ID: 8993851
[TBL] [Abstract][Full Text] [Related]
10. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition.
Mooser V; Nussberger J; Juillerat L; Burnier M; Waeber B; Bidiville J; Pauly N; Brunner HR
J Cardiovasc Pharmacol; 1990 Feb; 15(2):276-82. PubMed ID: 1689424
[TBL] [Abstract][Full Text] [Related]
11. Need for plasma angiotensin measurements to investigate converting-enzyme inhibition in humans.
Nussberger J; Juillerat L; Perret F; Waeber B; Bellet M; Brunner J; Ménard J
Am Heart J; 1989 Mar; 117(3):717-22. PubMed ID: 2537557
[TBL] [Abstract][Full Text] [Related]
12. Greater blood pressure-lowering effect of the renin inhibitor EMD 58265 than an angiotensin-converting enzyme inhibitor in two-kidney one-clip Goldblatt rabbit.
Zimmerman BG
Clin Exp Pharmacol Physiol; 2000; 27(5-6):370-7. PubMed ID: 10831238
[TBL] [Abstract][Full Text] [Related]
13. What we would like to know about the antihypertensive mechanisms of angiotensin converting enzyme inhibition.
Brunner HR; Waeber B; Nussberger J
J Hypertens Suppl; 1988 Dec; 6(3):S1-5. PubMed ID: 3066876
[TBL] [Abstract][Full Text] [Related]
14. The role of tissue renin-angiotensin systems in hypertension and effects of chronic converting-enzyme inhibition.
Keuneke C; Yacullo R; Metzger R; Hellmann T; Peters J; Ganten D
Eur Heart J; 1990 May; 11 Suppl D():11-6. PubMed ID: 2163328
[TBL] [Abstract][Full Text] [Related]
15. Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word?
Hollenberg NK; Fisher ND
Hypertension; 1995 Oct; 26(4):602-9. PubMed ID: 7558219
[TBL] [Abstract][Full Text] [Related]
16. Experience with perindopril in normal volunteers.
Waeber B; Nussberger J; Perret L; Santoni JP; Brunner HR
Arch Mal Coeur Vaiss; 1989 May; 82 Spec No 1():35-41. PubMed ID: 2549899
[TBL] [Abstract][Full Text] [Related]
17. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
18. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril.
Edling O; Bao G; Feelisch M; Unger T; Gohlke P
J Pharmacol Exp Ther; 1995 Nov; 275(2):854-63. PubMed ID: 7473177
[TBL] [Abstract][Full Text] [Related]
19. Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects.
Burnier M; Brunner HR
Exp Nephrol; 1996; 4 Suppl 1():41-6. PubMed ID: 9001896
[TBL] [Abstract][Full Text] [Related]
20. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
